“Look, as Geoff mentioned, the growth is not a one-off thing in '25 or in Q4 '25. It's going to carry into '26. And some of the new products that are carrying this are going to carry us well into '27.”

In context

“he supply chain team with Greg has kicked off a lot of very positive initiatives and we're starting to see the results. And I think there's more to come. So I'll be focusing on that deeply. And then on the below-the-line items, sure on the tax front, we'll keep working it. Some of the increase between ‘25 and ‘26 is due to the temporary safe harbors that we've got in Pillar 2. And there is uncertainty in terms of our ability to qualify for some of those safe harbors going into next year. And we’ll do everything we can to secure, being able to capture that opportunity. So sure, we'll be working on it. So look, we've tried to give a guidance. That's all in, and we'll work from there. You also had a part of the question on '27. Sorry, I wanted to address your -- the ’27 part of the question. Look, as Geoff mentioned, the growth is not a one-off thing in '25 or in Q4 '25. It's going to carry into '26. And some of the new products that are carrying this are going to carry us well into '27. So, Geoff mentioned CAS and Ardian and Tibial that will start having a small impact towards the end of '26 and we'll carry into '27. So first, we expect to continue to have good growth into '27, and that's regardless of the separation of the diabetes business. Just to give you some clarity on that. Diabetes drives about 40 basis points of our growth. So, we're comfortable we could still achieve the mid-single-digit growth even after the diabetes separation. We'll continue to drive the cost-out initiatives, as I mentioned earlier, FX should start turning into a small headwind towards the end of '26 and into 27. And the last item I wanted to mention is, we'll probably talk about it more in detail on the rest of the conversation. But the deal that we're -- the structure that we're taking on”